Thursday 22 May 2025

 

08.00-09.00

Registration

 

08.45-09.00

Welcome Esvonc to Oporto

 

 

 

Optimizing Cancer Therapy: Predictive Response, Dose Intensity, and Emerging Agents

 

09.00-09.30

Prediction of drug response in human oncology based on genomics

Dr. Fernanda Estevinho

09.30-10.15

Drug dose and drug choice: Optimizing medical therapy for veterinary cancer: dosing schemes, novel combinations, and patient-specific dosing or selection of agents

Dr. Dan Gustafson

 10.15-10.45

 Coffee break

 

10.45-11.15

Molecularly Targeted Agents in Veterinary Medicine: Optimal Use of New Drugs Becoming Available to Veterinary Oncology

Dr. Dan Gustafson

11.15-11.45

Revisiting Chemotherapy Dose Intensity and Antibiotic Prophylaxis in Veterinary Oncology: Clinical Impacts and old dogmas

Jessica Lawrence

11.45-12.15

Panel discussion

Speaker Panel

 

12.15-14.15

 

Lunch & Poster session

 

14.15-14.45

Sponsored talk by IDEXX

IDEXX Cancer Dx™: What is it and what do I need to know?

This educational session will focus on the innovation and impact of a new diagnostic tool for the early detection of lymphoma in canines, IDEXX Cancer Dx™. Attendees will learn the scientific foundation, clinical applications and how this diagnostic tool is revolutionizing veterinary practices by allowing broader access to cancer diagnostics.

 

 

 

Clemence Peyron, DVM, DESV-Médecine Interne

 

General abstracts

 

15.00-15.12

Genetic Signatures of Therapeutic Response in Canine Cancers

Dawn Duval
 15.12-15.24

Using evolutionary constraint to identify functional mutations in the non-coding space of canine osteosarcoma and diffuse large b-cell lymphoma.

 

Maja Arendt

 15.24-15.36  A novel screening platform for personalized molecular targeted therapy in veterinary oncology

Namiko Ikeda

15.36-15.48

Evaluation of whole-body diffusion-weighted imaging for the staging of canine multicentric lymphoma

Laura Barrett

15.48-16.00

A Novel Anti-CD20 mAb for Treatment of Canine B-cell Lymphoma: Pharmacokinetic and Safety Assessment

Andi Flory

 

16.00-16.30

 

Coffee break

 

 

Residents abstracts

 

16.30-16.42

Mediastinal lymphoma in 70 dogs treated with lomustine or anthracycline-based multi-agent chemotherapy: a multicenter retrospective study

Diogo Machado

16.42-16.54

Evaluation of a multidrug chemotherapy protocol including alkylating agents for treating canine high-grade T-cell lymphoma

Hannah Versteegh 
16.54-17.06

Computed tomography features of salivary glands neoplasia in dogs

Riccardo Finotello

17.06-17.18 Extracellular Vesicles from Canine Hemangiosarcoma Cell Lines as Potential Anti-Cancer Drug Delivery Systems

Yasmine Dadi

17.18-17.30

Preliminary Evaluation of Thalidomide as a Rescue Therapy for Canine Multiple Myeloma

Stefano Ciccarelli

 

17.30-18.00

 

ESVONC Clinical Research Fund

 

ESVONC CRF Committee

     

 

19.00-21.00

 

Welcome Reception

Supported by Boehringer Ingelheim